Heartflow, Inc. Common Stock (HTFL) - Stock Analysis
Last updated: Mar 23, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong gross margins • Large operating losses • Significant cash burn HTFL has a strong liquidity and product-level margin profile but is loss-making with substantial cash burn and a rich valuation that elevates execution risk.
Price Behavior
Key Price Behavior Insights: • Modest upside • Rapid rebound • Elevated volatility Support Level: $20.50 Resistance Level: $26.00 Over the last month HTFL shows a modest ~3–4% gain after a steep intraperiod drop to $20.49 and a rapid rebound into $25–26, leaving near-term resistance around $26.00 and support near $20.50 while momentum remains mixed and volatility elevated.
Sentiment & News
Key News Insights: • Revenue acceleration • Clinical expansion • Institutional buying HeartFlow reported robust commercial momentum with Q4 revenue up 40% to $49.1M, FY25 >$176M and 2026 guidance for ~25% revenue growth to $218–222M alongside expanding clinical programs and new institutional stakes.
AI Summary
HeartFlow has moved from a pre-commercial story to a revenue‑growth, high‑gross‑margin commercial play—driven by Aetna/payer wins that can unlock utilization upside—but the key actionable risk is whether management can convert payer coverage into sustained site adoption and operating‑cash‑flow improvement fast enough to avoid dilution given rich valuation and ongoing cash burn.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Active | +0.0% |